Shin S, et al. - A meta-analysis of relevant randomized controlled trials (RCTs) identified from a database search (Cochrane Library and PubMed) was carried out to evaluate the overall incidence and risk of common toxicities associated with bevacizumab in patients with advanced or metastatic breast cancer and to descriptively review study results concerning a potential relationship between bevacizumab-induced hypertension and its efficacy for breast cancer treatment. Among patients with advanced-stage breast cancer, the addition of bevacizumab to anticancer therapy was associated with a significant increase in the risk of high-grade adverse events, including hypertension, proteinuria, bleeding, cardiac toxicity, and neutropenic fever. The role of elevated blood pressure as a prognostic biomarker for its antitumor efficacy remains controversial although several retrospective studies suggested a predictive importance of hypertension secondary to bevacizumab therapy.